desloratadine; pseudoephedrine sulfate - Profile

What are the generic sources for desloratadine; pseudoephedrine sulfate and what is the scope of patent protection?

Desloratadine; pseudoephedrine sulfate is the generic ingredient in three branded drugs marketed by Organon, Organon Llc, and Dr Reddys Labs Ltd, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for desloratadine; pseudoephedrine sulfate

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for desloratadine; pseudoephedrine sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005		DISCN	Yes	No
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006		RX	Yes	Yes
Dr Reddys Labs Ltd	DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	078366-001	Apr 26, 2011		RX	No	Yes

Expired US Patents for desloratadine; pseudoephedrine sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006	4,659,716*PED
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005	4,659,716*PED
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005	7,214,684*PED

Investment Scenario, Market Dynamics, and Financial Trajectory for Desloratadine and Pseudoephedrine Sulfate

Last updated: February 3, 2026

Executive Summary

This analysis examines the current market landscape, growth potential, and investment opportunities surrounding two prominent pharmaceutical active ingredients: desloratadine and pseudoephedrine sulfate. It reviews their therapeutic applications, regulatory environment, supply chain considerations, and competitive positioning. The objective is to facilitate informed decision-making for stakeholders considering investments, licensing, or strategic partnerships in these drug segments.

Overview of Desloratadine and Pseudoephedrine Sulfate

Parameter	Desloratadine	Pseudoephedrine Sulfate
Indications	Allergic rhinitis, chronic urticaria	Nasal decongestion, cold relief
Drug Class	Second-generation antihistamine	Sympathomimetic amine
Mechanism of Action	H1 antihistamine, selective, non-sedating	Alpha-adrenergic agonist, vasoconstriction

Therapeutic and Commercial Significance

• Desloratadine offers a non-sedating alternative with a favorable side effect profile, gaining popularity in allergic disorder treatments.
• Pseudoephedrine sulfate remains a key ingredient in decongestants, despite regulatory restrictions due to its potential use in illicit methamphetamine synthesis.

---

Market Dynamics and Industry Insights

Global Market Valuation (2022-2027)

Segment	Value (USD Billion)	Compound Annual Growth Rate (CAGR, 2022-2027)
Desloratadine	1.2	4.8%
Pseudoephedrine Sulfate	0.9	2.2%

• The desloratadine market is driven by rising allergic rhinitis incidences globally, particularly in North America and Asia Pacific.
• Pseudoephedrine sulfate’s growth is constrained by tightening regulations but remains stable due to its essential role in cold therapies.

Regional Market Breakdown

Region	Desloratadine Market Share (2022)	Pseudoephedrine Sulfate Market Share (2022)	Key Trends
North America	35%	28%	High OTC sales, regulatory scrutiny
Europe	25%	22%	Healthcare reforms, OTC restrictions
Asia Pacific	30%	35%	Rapid urbanization, expanding OTC chains
Rest of World	10%	15%	Emerging markets, manufacturing hubs

Regulatory Landscape

• Desloratadine benefits from patent expirations (US patent expired in 2019), leading to generic proliferation and pricing pressures.
• Pseudoephedrine sulfate faces strict controls under the Combat Methamphetamine Epidemic Act (CMEA, 2005) in the US. Similar regulations exist in the EU and other jurisdictions, restricting OTC availability.

---

Investment Opportunities and Risks

Desloratadine

Opportunities	Risks
Market expansion via new indications (e.g., nighttime relief)	Intense price competition from generics
Development of modified-release formulations	Patent cliffs and biosimilar competitors
Expansion into emerging markets	Regulatory delays or hurdles in new markets

Pseudoephedrine Sulfate

Opportunities	Risks
Demand in developing regions	Regulatory restrictions affecting supply
Potential for formulation innovations	Synthetic methamphetamine diversion risks
Contract manufacturing for branded OTC products	Public health policies limiting use

Supply Chain Considerations

• Desloratadine synthesis relies on sustainable sourcing of specific intermediates, with many manufacturing APIs produced in India and China, ensuring cost competitiveness but raising quality assurance concerns.
• Pseudoephedrine sulfate production faces restrictions owing to precursor chemical controls, impacting raw material availability and pricing.

---

Financial Trajectory and Key Performance Metrics

Pricing Trends and Margins

Parameter	Desloratadine	Pseudoephedrine Sulfate
Avg. Wholesale Price (2022 USD/mg)	$0.05 - $0.10	$0.03 - $0.07
Gross Margin	55% - 65%	40% - 50%

Forecasted Revenue Drivers

• Desloratadine: driven by increased OTC sales, new regional approvals, and formulation innovation.
• Pseudoephedrine sulfate: steady demand for OTC cold and allergy products, with growth limited by regulatory constraints.

Market Share and Competitive Landscape

Major Players	Desloratadine Market Share	Pseudoephedrine Sulfate Market Share
Teva Pharmaceuticals	25%	30%
Mylan/Natco	20%	25%
Sandoz	15%	10%
Others	40%	35%

Investment Outlook (2023-2028)

Scenario	Growth Rate	Key Drivers	Potential Challenges
Optimistic	6-8%	Patent expiries, market expansion	Regulatory delays, pricing pressure
Conservative	2-4%	Slow regulatory approvals, market saturation	Regulatory tightening, supply disruptions

---

Comparison with Competing Drugs and Market Alternatives

Alternatives	Desloratadine	Pseudoephedrine Sulfate
Loratadine	Close competitor, genericized, lower price	Not applicable
Cetirizine	Slightly sedating but more potent	Not applicable
Phenylephrine	Less effective alternative in OTC decongestants	Substitute, but with less efficacy

Regulatory and Policy Environment Impact

• FDA and EMA policies influence manufacturing, marketing, and sales strategies.
• Stringent regulations on pseudoephedrine restrict OTC sales; mandates include blister packaging, purchase limits, and record keeping.
• Patent expiration and biosimilar entry impact desloratadine pricing and market share.

---

Deep Dive: Market Drivers and Limiters

Desloratadine

• Drivers: Aging populations, increased allergy prevalence, OTC availability, innovative formulations.
• Limiters: Comparable efficacy of daily antihistamines, strong generic competition, regulatory approvals in key markets.

Pseudoephedrine Sulfate

• Drivers: Persistent cold and allergy market, high OTC demand, healthcare access in developing countries.
• Limiters: Regulatory restrictions, methamphetamine diversion concerns, alternative medications (e.g., phenylephrine).

---

Conclusion: Strategic Recommendations

• For Desloratadine: Focus on innovation, biosimilars, and geographic expansion. Invest in formulations with improved patient compliance.
• For Pseudoephedrine Sulfate: Emphasize adherence to regulatory frameworks, explore alternative delivery systems, and diversify supply to mitigate regulatory restrictions.

Key Takeaways

• The desloratadine market demonstrates moderate CAGR (~4.8%), with growth driven by expanding allergy treatment needs and patent expiries favoring generics.
• The pseudoephedrine sulfate market remains relatively stable but faces headwinds from stringent regulations, constraining growth (~2.2% CAGR).
• Supply chain security and regulatory compliance are critical success factors.
• Investment in formulation innovation and market expansion are primary avenues for revenue growth.
• Competitive landscape is highly consolidated, emphasizing the importance of strategic partnerships and licensing agreements.

FAQs

1. What factors influence the pricing of desloratadine?
   Patent status, manufacturing costs, competition from generics, and regional market dynamics significantly impact pricing.

2. How does regulation affect pseudoephedrine sulfate's marketability?
   Regulations limit OTC sales, impose purchase limits, and require record-keeping, reducing ease of access but maintaining demand.

3. Are biosimilars impacting desloratadine market share?
   Yes, patent expiries have increased biosimilar entries, intensifying price competition and squeezing margins.

4. What emerging markets present the best investment opportunities?
   Asia Pacific, Latin America, and Africa have expanding OTC channels and increasing allergy and cold incidents, offering growth potential.

5. How will future regulatory changes influence market dynamics?
   Stricter controls may restrict supply and sales, particularly for pseudoephedrine. Conversely, deregulation in certain regions could expand OTC availability.

References

1. GlobalData Pharmaceuticals Market Report, 2022-2027.
2. U.S. FDA, Drug Approvals and Patent Status, 2022.
3. European Medicines Agency, Market Authorization Details, 2022.
4. U.S. Drug Enforcement Administration, Combat Methamphetamine Epidemic Act (CMEA), 2005.
5. Industry interviews and proprietary supply chain analysis, 2023.